Caplin Point Laboratories Ltd
CAPLIPOINT
Scorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| PE RatioPE Ratio | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.37 | 3.45 | 0.58% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 34.15 | 4.18 | 0.92% |
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Caplin Point Laboratories Limited is a pharmaceutical company. The Company's product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Pain Management and Anti-ulcers.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Abbott India Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Board Meeting Intimation
CAPLIN POINT LABORATORIES LIMITEDhas informed the Exchange about Board Meeting to be held on 11-Feb-2023to inter-alia consider and approve the Unaudited financial results of the Company for the Quarterly ended December 2022 . | Download
CAPLIN POINT LABORATORIES LIMITEDhas informed the Exchange about Board Meeting to be held on 11-Feb-2023to inter-alia consider and approve the Unaudited financial results of the Company for the Quarterly ended December 2022 . | Download
Cash Dividend
Final • Div/Share: ₹ 2
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant